Eisai , Ltd. Overview
Valuation check: ESALF's ROE is 3.5%, below the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow3.50%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ESALF is 3.5%. That is below the Healthcare sector average of 11.15%. Investors often review this figure alongside Eisai , Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ESALF currently prints 3.5% for ROE, while the sector average sits near 11.15%. That is roughly 68.7% below the sector mean. Large gaps often invite a closer look at Eisai , Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively Eisai , Ltd. converts resources into returns. At 3.5%, ESALF may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ESALF's ROE (3.5%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Eisai , Ltd.'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
